Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce a definitive license and supply agreement with Navilyst Medical, a leading manufacturer of image-guided medic

Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce that Fresenius Medical Care (NYSE: FMS), the worlds' largest integrated provider of dialysis products and ser

Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce the addition of Mr. Kevin Palmer to the IBI management team as Vice President of Finance.

Toronto, Canada, February 14th, 2011 – For Immediate Release Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce the appointment of Arthur L. Rosenthal to Cha

At work developing transformative biomedical-polymer products, Interface Biologics, a private company, has recently completed a $7M series B financing led by Business Development Bank of Canada in conjunction with Covington Capital and VG Partners.

Toronto, Canada, January 10th, 2011 – For Immediate Release Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce the completion of a $7M series B financing, le